Huntington's disease (HD) is a hereditary neurodegenerative ... The movement disorder is characterized by involuntary movements known as chorea, and by the impairment of voluntary movements. The ...

A new discovery offers hope for Huntington’s disease. This discovery provides hope that a DNA repair process may help slow or ...

SOM3355 (bevantolol hydrochloride) hit its objectives in a phase 2 trial in patients with Huntington's disease, improving the involuntary, jerky movements known as chorea that are a key symptom of ...

The FDA has approved Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD). Formerly known as SD-809, Austedo is the first drug containing ...

I have been talking with a friend at work whose husband has Huntington’s disease. I have learned a lot in the couple of conversations we have had discussing this unforgiving condition. She ...

Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

The fellows gain expertise in diagnosing and treating Parkinson’s disease, atypical Parkinsonian syndromes, dystonia, tremor, Huntington’s disease, chorea, myoclonus, ballism, Tourette syndrome, tics, ...

Huntington’s disease used to be called Huntington’s chorea because it is the most commonly inherited condition to lead to the involuntary movements referred to as chorea. A new drug-free ...